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THE TREATMENT OF RHEUMATIC CARDITIS:

SALICYLATES vs. STEROIDS

For the past twenty years, the treatment of rheumatic fever has
evolved around two drugs, salicylates and steroids.

During this time,

a great deal of literature and controversy has accumulated concerning
the relative merits of these two therapeutic approaches.

It has been

generally appreciated that both drugs are effective in controlling joint
symptomatology, fever and other toxic manifestations of the disease.
However for the most part rheumatic fever is a self-limited disease, and
carditis is the only rheumatic manifestation which results in sequelae.
Thus, it is the treatment of rheumatic carditis and the prevention of
residual heart disease that has primarily concerned investigators in the
field.
Salicylates were first popularized for the treatment of rheumatic
fever in 1876 by Maclagan.

13

His remedy was extracted from the bark of

a willow belonging to the Salicaceae family.

Following his discovery,

salicylates in varying dosages became immensely popular in the treatment
of rheumatic fever.

It was not until 1949 when Hench

lO

introduced ster-

oids to rheumatic therapy that the superiority of salicylates was challenged.

Subsequently numerous contradictory reports concerning the

advantages and limitations of these two therapeutic regimens were published and the need for a carefully controlled study became essential.
Clinical trials of therapeutic agents for a disease as unpredictable
and variable as rheumatic fever are beset with many pitfalls, which may
invalidate the findings.

Stollerman
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in his review of the subject re-

marked, lilt should be obvious that the variables involved in matching
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groups of patients to therapeutic trials are so numerous that few
studies can satisfy all criticism of their design.'!) Many factors must
be taken into consideration.

In order to exclude the possibility of

previous injury to the heart, a complete history is essential to confirm
that the rheumatic episode represents a first attack.

Furthermore, the

symptoms must be of relatively short duration, otherwise irreversible
changes may have occurred before treatment is initiated.

Secondly, the

drugs must be administered concurrently to prove the superiority of one
over the other.

Results obtained in studies undertaken in previous years

cannot be used for comparison as it appears that the severity of rheumatic fever is declining and its pattern changing. 19

Thirdly, cardiac

status at the time therapy is instituted must be strictly defined and
treatment groups must be comparable as to severity of carditis.

Patients

with mild carditis should be excluded, because irrespective of therapy
they tend to recover without residual heart disease.
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Finally, to in-

sure complete objectivity, patients must be allocated to their respective
treatment groups on a blind and random basis.
It is the purpose of this paper to review and criticize the various
controlled studies concerning the treatment of rheumatic carditis.

Em-

phasis will be placed on the U.K. and U.S. Cooperative Report as it is
very comprehensive and represents a model clinical trial.

Therapeutic

concepts will be summarized and a program of rheumatic therapy proposed.
In 1950, when steroids became available the need for a controlled study
was apparent in order to obtain definitive information on the value of
these drugs in the treatment of rheumatic fever.

-

Twelve research centers

in Great Britain, Canada and the United States embarked on a cooperative
study under the sponsorship of the American Heart Association, and the

Medical Research Council of Great Britain.
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The study was designed

to compare the therapeutic effects of the hormones, ACTH and cortisone.
with the usual treatment of rheumatic fever at the time.
to be sought to two questions:

Answers were

(1) What is the relative effectiveness

of each of these hormones and of aspirin in altering the course of the
acute disease in suppressing its clinical manifestations?

(2) What is

the relative effectiveness of these three agents in preventing rheumatic
heart disease?
Only children under 16 years of age who met the modified Jones criteria (1955) for the diagnosis of rheumatic fever were included in the
study.

In all, 497 patients were accepted and allocated at random to

treatment with one of the three drugs - ACTH, Cortisone or Aspirin.

Each

regimen was given for six weeks according to a defined schedule and detailed observations were continued for an additional three weeks.

Follow-

up examinations were made at specific times after these nine weeks, and
the first report extended one year from the initial nine weeks.
DOSAGE SCHEDULES OF U.K. AND U.S. REPORT
DRUG
Acety1salic;:ylic Acid

Cortisone

ACTH

DAILY DOSE

DAY OF TREATMENT

60 mg/1b
40 mg/1b
30 mg/1b
300
200
100
75
50

1-2
3-7
8-42

mg
mg
mg
mg
mg

U.K CASES
80 USP units
60 USP units
40 USP units
30 USP units
20 USP units

1
2-5
6-21
22-35
36-42
U.S. CASES
120 USP units
100 USP units
80
60
40
20

USP
USP
USP
USP

units
units
units
units

1-4
5-7
8-21
8-14
14-21
22-35
36-42

As will be noted, many critics of this study considered the hormone
dosages too small and the treatment period too short.

On the other hand,

nearly all cases receiving hormones developed Cushingoid cosmetic effects.
All patients received penicillin to maintain therapeutic levels for
14 days to eradicate streptococci foci, followed by oral sulfadiazine to

prevent intercurrent streptococcal infections during the hospital stay and
throughout the follow-up period.

All patients were kept at bed rest for

the nine weeks of therapy and observation.
The three treatment groups were further subdivided into three groups
according to the length of time of each case between the date of onset of
the attack and the date at which therapy began.

The three duration - from -

onset groups were (1) 14 days or less; (2) 15-42 days; (3) 43 days and
over.

Of the 497 cases, just over half (255) began therapy within 14 days

within onset of the attack and 60 per cent of these (149) were treated
wi thin one week of ons e t.

In near ly two- thi rds (327) there was nei t-her

history of a previous attack of rheumatic fever, or evidence of pre-existing
rheumatic heart disease.

Approximately one-fourth (128) of the 497 cases

were definitely diagnosed as having pre-existing rheumatic heart disease
at the start of therapy.
Random construction of the three treatment groups caused them to be remarkably similar in many aspects such as;

the treatment - from - onset pe-

riod, age, sex, weight, temperature, pulse during sleep, erythrocyte sedimentation rate (ESR), frequency of polyarthritis, incidence of subcutaneous nodules, incidence of erythema marginatum, and incidence of basal
diastolic murmurs.
-.

However, two differences exist:

(1)

The aspirin group

included more patients with chorea as a presenting symptom (15.5%) than ACTH
(5.6%) and cortisone 01.4%)

(2) The ACTH group had a larger proportion

of severe carditis represented by congestive heart failure and/or pericarditis.
aspirin.

Such cases numbered 27 for ACTH, 24 for cortisone and 17 for
The fact that fewer cases of severe carditis were present in

the aspirin group has also been criticized by those who maintain that
differences in drug effectiveness are most evident in very severe car" . 4
d l.tl.S.

It is also noted that four cases in the aspirin group were

eventually administered hormone treatment because of the severity of
their illness.

Statistically, these four cases remain in the aspirin

group but' are none the less indicative of some investigator bias concerning the treatment of severe cases.
During the acute illness and the first year follow-up, six deaths
occurred, one in the ACTH, two in the cortisone and three in the aspirin
group.

Two of the three aspirin deaths were switched to hormone therapy

prior to death.

Apart from the six deaths, there were some in each

group who, during the one year period, were retreated for persisting
or recurring manifestations.

Retreatment was given to 10 of the 161

ACTH cases surviving to one year, 8 of the 165 cortisone cases surviving
to one year, and 19 of 165 aspirin cases surviving to one year.

However

further analysis of these cases shows that the greater proportion of
retreatment in the aspirin group occurred primarily among the chronic
cases (43 days or more between onset and treatment) and was influenced
by the larger number of cases initially admitted with chorea to the
aspirin group.
It is important to note that practically all the ACTH and cortisone
cases showed one, or a combination. of the following side effects of
therapy:

moonface, hirsutism, acne or stria.

There were only 10.5%

of the ACTH and 4.8% of the cortisone without any of these side effects

by the end of the ninth week.

In addition to these side effects many

others were reported, but not tabulated.

These included cases of hyper-

tension, mental symptoms, convulsions, renal hemorrhage, water and salt
retention, glycosuria, infections, hepatomegaly, febrile reactions,
pigmentation, increased fat deposition and unusual increase in appetite.
Furthermore relatively few aspirin cases developed side effects.

There

were 26.7% of the aspirin group that developed side effects such as
tinnitus or deafness, nausea or hyperventilation.

These side effects

all appeared in the first week of therapy while the aspirin dosage was
relatively high and promptly disappeared when the dosage was reduced.
The report concluded that:

(1) The temperature and pulse rate

during sleep returned to normal during treatment in the great majority
of cases in all treatment groups, but there was a greater tendency in
the groups treated with the hormones for them to become elevated in the
6-9 week observation period.

(2) The erythrocyte sedimentation rate

decreased more rapidly during treatment in the hormone treated group
but was elevated more frequently in the 6-9 week observation period.
There were no differences between treatment groups at the thirteenth
week.

The temperature, pulse and ESR re-elevation during the observa-

tion period was later termed "rebound phenomena."

(3)

The behavior of

joint involvement, chorea and erythema marginatum was essentially the
same in the three treatment groups.

Nodules, however, disappeared

more rapidly in the patients treated with hormones although new nodules
appeared in some patients during treatment in all three groups.
In the evaluation of the cardiac status of their cases, the study
used the parameters of heart size, PR interval, murmurs and congestive
heart failure, and/or pericarditis.

Cases were further subdivided into

three cardiac groups:

(A) those without pre-existing heart disease

or current carditis; (B) those currently with carditis but without
pre-existing heart disease; (C) those with pre-existing heart disease.
The study reported that when heart size was measured by the proportion of patients with a cardiothoracic ratio of .55 or more, the
cardiac subgroups and the total cases revealed no differences between
treatment up to and including the one year follow-up period.

The PR

intervals decreased more frequently and rapidly in the hormone groups
than in the aspirin group.

This difference lessened during the obser-

vation period and was absent at nine weeks and one year.

It may be

questioned whether the early decrease in PR intervals in an effect of
the hormones on the disease or merely a direct effect on the atrioventribular conduction time.

Also, it was reported that there appeared

to be no relationship between treatment groups and the appearance or
disappearance of congestive heart failure and pericarditis.
Concerning murmurs, findings indicated:

(1) The development of

an apical systolic murmur, or basal diastolic murmur among those without such murmurs at the start of therapy, regardless of the presence
or absence of carditis, was infrequent and not related to therapy.
(2) The

disap~earance

of soft apical systolic murmurs was more rapid

among the hormone groups than among those receiving aspirin, but at the
end of one year the treatment groups did not differ significantly.
(3) The disappearance or diminution of loud apical systolic murmurs
rarely occurred regardless of therapy.

(4) At the end of one year there

was no evidence that the treatment groups differed in the frequency with
which murmurs had appeared or disappeared.
In summary, the report concluded that there was no evidence that

any of the three agents resulted in uniform termination of the disease.
Treatment with either of the hormones resulted in more prompt control
of certain acute manifestations, but this more rapid disappearance was
balanced by a greater tendency for the acute manifestations to reappear
for a limited period upon cessation of treatment (rebound phenomena).
Treatment with the hormones also leads to the more rapid disappearance
of nodules and of soft apical systolic murmurs.

However at the end of

one year, there was no significant difference between the treatment
groups in the status of the heart.
In October 1960, the five year report of the U.K and U.S. Cooperative Clinical Trial was published.
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At this time, 445 of the original

497 cases were known to be alive (89.5%) and 16 were known to have died
(3.2%).

Thus 92.7% of the 497 cases were traced at 5 years.

The find-

ings of the report confirmed those reported at one year, in that there
was no appreciable difference in the cardiac status of the three treatment groups, and thus the prognosis had not been influenced by one treatment more than another.

The Report was however, able to definitely cor-

relate cardiac prognosis with the status of the heart at the time treatment was initiated.

For cases without carditis initially the prognosis

was excellent since in 96% there was no residual heart disease.

In

cases with carditis initially but without pre-existing heart disease
the proportion without residual heart disease decreased progressively
from 82% for those with only a grade I apical systolic murmur to 30% for
those with failure and/or pericarditis.
disease the prognosis was poor.

In cases with pre-existing heart

Only 30% of those without pericarditis

or failure and none of those with pericarditis or failure were without
heart disease at 5 years.

Most of the deaths from rheumatic fever

(10 of 14) occurred among cases with pre-existing heart disease and
there were no deaths among the cases without heart involvement at
the beginning of treatment.

All in all, the report concluded that

the treatment of rheumatic fever cannot be properly evaluated unless
the cardiac status at the start of therapy is taken closely into account as this is probably the most important factor in the prognosis.
In September 1965, the ten year report was released.
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Three

hundred and ninety-seven cases <79.9%) were known to be alive at ten
years and 19 (3.8%) were known to have died from rheumatic fever or
rheumatic heart disease.

Again, it was confirmed that prognosis had

not been influenced by treatment and that the initial cardiac status
was the most important prognostic factor.

It was also noted that the

fatality rate was very low in each of the groups, indicating that the
patients had done well regardless of treatment.
Following the Cooperative Study, numerous reports were published
advocating the superiority of steroids in the treatment of rheumatic
carditis.

For the most part, these studies were uncontrolled and based

on the premise that the steroid dosage of the Cooperative Study had been
too low and administered for too short a time.
workers (1952)

9

Greenman and his co-

were among the first to report good results with 300 mg.

of cortisone given daily for 6 to 8 weeks to patients in their initial
attacks of rheumatic carditis.

With this regimen the author observed

a very low residual of heart disease.

Other investigators reporting a

low incidence of residual heart disease in patients treated with large
amounts of steroids for 10-12 weeks include Markowitz and Kuttner,
1955,14 Roy and Hassell, 1956,22 Ferencz et al., 1959;7 Massell et al.,
1961.

18

In 1957 Illingworth
six treatment groups:

ll

published the results of a comparison of

(1) no specific treatment; (2) salicylates in

low dosage; (3) salicylates in high dosage; (4) steroids alone; (5) steroids with salicylates in low dosage; (6) steroids with salicylates in
high dosages.

The study concluded that cortisone was superior to sali-

cylates and that cortisone combined with salicylates, especially in
high dosage was superior to cortisone alone in the treatment of rheumatic fever.

However, this study is a retrospective study encompassing

200 children treated over a period of 9 years.

The patients were not

allotted to the respective treatment groups in a blind random basis and
were not treated concurrently.

Over one-fourth (55) of the children

were not part of any controlled study, but were blended in with the controlled.

The groups were grossly dissimilar numerically ranging from

61 in the high dosage salicylate group to 16 in the low dosage salicylate group.

Moreover, the proportion of patients in each of these groups

with carditis is even more distorted.

Evidence of carditis was almost

exclusively limited to the presence or absence of a murmur and there is
a notable lack of patients with severe carditis.

In summary, this study

is very interesting but cannot be classified as a valid study.
Uncontrolled studies reporting that prolonged intensive steroid
therapy would reduce the incidence of residual rheumatic heart disease
continued to be published and it became essential to have a concurrent
group of patients treated with sa1icy1ates.

In 1956 the pediatric ser-

vices of 8 hospitals situated in Baltimore, Boston, Cleveland and New
York combined in a study to compare large doses of prednisone given 12
weeks with acetylsalicylic acid given for a similar length of time,
What the study lacked in quantity it compensated in quality.

Fifty-seven

patients were allotted on a blind, random basis to the two treatment
groups.

Only patients with their first rheumatic episode, the onset

of which was within 28 days and who showed clinical evidence of moderate
to severe carditis, were admitted to the study.

Criteria for the diag-

nosis of carditis were the presence of one or more of the following:
pericardial rub or effusion, unequivical cardiac enlargement, congestive heart failure, significant aortic or apical diastolic murmurs or
Grade 3 apical systolic murmurs.

Twenty patients were allotted to the

prednisone group and twenty-eight assigned to the aspirin group.

Both

groups were comparable as to average age, onset to therapy interval and
cardiac status.

Prednisone dosage was 60 mg. daily for three weeks with

gradual reduction during the following nine weeks.

Aspirin was given at

50 mg/lb daily in divided doses for nine weeks, and then tapered over
the next three weeks.
Results obtained by the Combined Study were published in 1960.
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At the end of one year follow-up, no significant difference was observed
in the incidence of residual heart disease in the two treatment groups.
Furthermore, the study reported that regardless of treatment, the institution of therapy as late as 20-28 days after onset did not result
in a higher incidence of residual heart disease.

By the same token

even the prompt control of the acute symptoms did not prevent cardiac
damage in either treatment groups,

However, as was noted in the Coopera-

tive Study, a few patients (4) were changed from aspirin to prednisone
because of the severity of their manifestations and their lack of response to salicylates.

Of these four patients, one died.and after,l year

two had residual heart disease and one had a normal heart.

In this

study the patients were allotted to the two treatment groups on a random

single blind basis.

The decision to transfer these four patients re-

presents clinician bias.

The study admitted lithe majority of investi-

gators conducting this study are of the opinion that prednisone suppresses the inflammatory reaction of the acute rheumatic attack more
rapidly than acetylsalicylic acid and in patients with congestive
heart failure may be life saving. t1

Even though the group felt the

steroid dosage represented a definite risk, there w,ereno incidents of
serious untoward reactions to the therapy.
In contrast to the Combined Study, Dorfman and his associates

5

in

1961, reported that large doses of steroids continued for 12 weeks
were more effective than salicylates in the prevention of residual
heart disease.

His study encompassed 131 patients without a history

of a previous attack and treated within 18 days from the onset of their
attack, that met the modified Jones criteria.

Patients were randomly

and comparatively distributed into four treatment groups:

(1) hydro-

cortisone (2) aspirin (3) hydrocortisone and aspirin (4) no specific
antirheumatic therapy.

As customary, all four groups received penicillin

prophylaxis and were kept at bed rest as a basic regimen.

Patients

weighing more than 80 Ib received 250 mg. of hydrocortisone each day
for the first four days; then 100 mg. per day through the eighth week
after which the dosage was reduced gradually through the twelfth week.
Those weighing less than 80 Ibs were started on 200 mg., reduced 80 mg.
and then tapered.

Aspirin dosage was determined by blood level as 20

to 30 mg/100/ml was maintained through nine weeks and then tapered.
In reviewing Dorfman's study, it becomes apparent that he was
generally dealing with mild carditis.

Although his criteria for car-

ditis is noble, the incidence of pericarditis, congestive failure,

cardiac enlargement and diastolic murmurs is too small for any critical
evaluation.

In essence, Dorfman has based his findings on the incidence

of apical systolic murmurs.

Of the 85 patients admitted to the study

wi th "cardi tis" 67 09%) had minimal cardi tis manifes ted only as apical
systolic murmurs of grade 1 or 2 intensity.

It should be recalled that

the Combined Study required that an apical systolic murmur be of grade 3
intensity before accepted as sole criteria for carditis.
use 1-4 as a basis for gradation.

Both studies

As previously noted and emphasized by

the U.K. and U.S. Joint Report, patients with mild carditis, irrespective
of therapy, rarely develop residual heart disease.

However, it must be

conceded that Dorfman's statistics were impressively favorable toward
steroids in the abolishment of apical systolic murmur during the one year
follow-up.

These murmurs disappeared nearly three times as frequently in

the groups receiving hormones as opposed to the other regimens.

Dorfman's

data also showed that patients admitted to the study who did not have
organic murmurs have a low risk of developing them regardless of treatment.

Another important fact about this study is that it is one of the

few controlled studies to actually report serious therapeutic side effects.

Two patients in the aspirin plus steroid group developed bieed-

ing ulcers.
In an attempt to evaluate the relative merits of the two drugs in
severe carditis, Czoniczer published a retrospective study in 1964.

4

As many investigators, Czoniczer felt that the effect of aspirin and
steroids in preventing residual heart damage could best be judged on
those patients most likely to develop residual damage.

For this reason,

he selected 145 patients with severe rheumatic carditis as indicated by
congestive heart failure or pericarditis.

Patients were selected from

admissions to the House of the Good Samaritan between the years of
1939 and 1963.
parable.

Needless to say, treatment groups were far from com-

Dosage schedules were variable, selection was not random and

the groups were not treated concurrently.

Many of the aspirin group

did not receive penicillin therapy or prophylaxis and a larger proportion of the steroid group were observed in their initial attack.
Czoniczer attempted to minimize the dissimularities of his treatment
groups through subdivision analysis however, the groups remained
grossly incompatible.

His data the validity of which is questionable,

indicated a lower death rate and higher recovery rate with steroids.
Czoniczer concluded that steroids in high dosage were the treatment of
choice in severe rheumatic carditis.
Short-term high dosage steriod therapy was introduced by Wilson
· a serles
.
an d h er co-wor k ers ln

0

f papers b
· · ·ln 1953 • 28- 32
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She

reported that 100 - 160 mg. of prednisone given daily for an average
of 7 days and instituted early in the course of the disease would
terminate the rheumatic process and prevent residual heart disease.
In 1960, she stated, "Our observations clearly demonstrate that in
patients with progressive clinical symptoms of active carditis, adequate short-term hormone therapy will terminate the inflammatory process, significantly shorten the duration, and prevent or minimize
residual cardiac damage.,,28

However, none of Wilson ISS tudies in-

eluded concurrent observations on patients treated with salicylates
and her criteria for carditis was subject to much criticism.

Neverthe-

less, short-term intensive therapy was very appealing in that serious
untoward reactions to steroids rarely occur within one or two weeks,
and the length of hospital stay could be shortened.

In an attempt to confirm Wilson's result the Combined Rheumatic
Fever Study Group (1965) undertook a second study in which short term
intensive steroid therapy was compared with aspirin.

3

Seventy-three

children whose first rheumatic episode had occurred within 21 days of
the onset therapy and who exhibited moderate to severe carditis were admitted to the study.

Criteria for the carditis was rigid and identical

to that used in the first Combined Study.
signed to two treatment groups.

Patients were randomly as-

One group received 3 mg. of predni-

sone per pound of body weight daily up to a maximum of 200 mg/1b/day for
seven days.

The drug was then discontinued without tapering.

Patients

in whom definite signs of active carditis persisted after the seven
days received a second seven day course with the same dosage.

The second

group received aspirin, 50 mg/1b of body weight daily for six weeks and
then 25 mg. per pound per day for an additional two weeks.

The two

groups were comparable in most aspects except that more patients with
congestive heart failure and cardiac enlargement were randomly allotted
to the aspirin group.

Patients were followed for one year after the

completion of therapy.
The study was conducted over a four and a half year period.

During

the first two years of the study, three children receiving aspirin were
transferred to the prednisone group because of the severity of their
carditis.

The investigators realized that this represented a clinical

bias and accordingly conducted the last two and a half years of the
study on a double-blind basis.

During this period there were no devia-

tions from the prescribed medication.

In 1965, the study reported that

there was no significant difference in the incidence of residual rheumatic heart disease in either the single-blind or the double-blind series.

Of the 34 patients who received prednisone, 15 still showed signs of
active carditis after their seven day treatment course.

These 15

patients were given a second seven day course after which 8 of the
15 again showed active carditis.

After one year, more than half of

the prednisone patients (19 of 34, or 55.8%) had residual rheumatic
heart disease.

Similarly after one year 25 of 39, or 64.1%, of the

aspirin group had heart disease.

The differences between treatment

groups were small and not statistically significant.
Obviously, the Combined Study could not confirm Wilson's remarkable results.

We can assume then, that Wilson's loosely constructed

studies were probably based on patients with mild carditis, the majority
of whom would not have residual heart damage regardless of therapy.

How-

ever, the Combined Study also reported that the high dosage of prednisone
was well tolerated, rebound phenomena were minimal and no untoward reactions were encountered.

They further added that it was their clini-

cal impression that "steroids were useful in controlling the exudative
phase of acute severe myocarditis in critically ill patients. ft

Their

recommendation was that steroids be given to severely ill patients
with myocarditis for one or two weeks to be followed by aspirin therapy
for six to eight weeks.
Perhaps the most recent comparative study is that by Stalzer
et a1

24

in which 135 airmen admitted to Warren Air Force Base Hospital

with rheumatic fever'were evaluated" Patients were randomly assigned
to aspirin, cortisone and ACTH groups.

A 14 month follow-up showed

that cortisone prevented the appearance of significant murmurs and
caused the disappearance of existing significant murmurs to a greater
degree than the other two.

However, Stolzer is very careful to deal in

impressive percentages.

Simple computation reveals that at the onset

of therapy, only 17 of the 135 patients had a carditis and the majority
of these had a mild carditis.

Therefore, little importance can be

given to the results of this study.
SUMMARY

In summarizing the findings of the various reports on rheumatic
therapy, a statement of Bywaters seems applicable.

"Broadly speaking,

the observers may be grouped as those with enthusiasm but no controls
and those with controls and no enthusiasm.
have obtained general agreement.

"1

However, certain aspects

First of all, the incidence of car-

ditis in initial attacks of rheumatic fever would seem to be somewhere
between 40-50%.

That is, at least 50% of rheumatic patients do not re-

quire intensive suppressive therapy to prevent residual heart disease.
With these patients, salicylates remain the treatment of choice.
Secondly, in those patients with carditis, the most important prognostic factor concerning residual damage is the initial cardiac status
at the time therapy is instituted.

Those patients with severe carditis -

congestive failure, pericarditis or unequivical cardiac enlargement have a poor prognosis as approximately 70% will develop residual heart
disease, irrespective of therapy.

Patients with mild or minimal car-

ditis, usually manifest as a grade I or II apical systolic murmur,
will commonly <75-80%) recover without residual damage regardless of
therapy.

Thirdly, it is generally accepted that neither steroids or

salicylates alter the duration of a rheumatic attack.
Spagnuolo

6

Feinstein and

have conducted extensive studies and concluded that the

average duration of acute inflammatory activity is 109.::!: 57 days with
or without treatment.

Finally and most importantly, there has been

no definite or consistent demonstration that cardiac damage is prevented or minimized by either salicylates or steroids given early or
late in the course of the illness, in high or low dosages, or for
long or short periods of time.
From the review presented it should become evident that the
selection of a suppressive agent can hardly be regarded as critical
to the outcome of most attacks of rheumatic fever.
cylates are palliative but not curative.

Steroids and sali-

Both drugs are effective

anti-inflammatory agents in controlling the toxic manifestations of
the disease such as fever and arthritis.

Steroids are a more potent

anti-inflammatory agent than aspirin and accordingly clinical observations have shown that the toxic effects of rheumatic fever are often
more rapidly controlled with steroids.

Not only are steroids more

promptly effective, but they are also tolerated better than aspirin
in the acutely ill patient and aften produce a feeling of well being.
Also instances in which the acute illness failed to respond to salicylates but was subsequently controlled by steroid therapy have been
well documented.

Now keeping in mind that there is no "proof" that

stero,ids reduce ultimate cardiac scarring, let us propose two practical
questions.

(1) Why would steroids not be likely to have a similar

prompt suppressive effect on acute edematous myocarditis?

It stands

to reason that the longer an acute infectious process persists the
more likely residual scarring will result.

(2) In a severe carditis

when the heart is laboring to remian compensated would it not be advantageous to reduce the added stressful burden of the toxic manifestations as rapidly as possible?
steroids.

'rhus, it is the time factor that favors

What then are the disadvantages of steroid therapy:

Namely

three; (1) side effects, (2) rebound phenomena and paradoxically
(3) too prompt of a suppression.

As has been previously noted, the

occurrence of Cushingoid cosmetic effects is a common observation
with prolonged steroid therapy.

Varying degree of weight gain, moon-

face, central obesity, "buffalo hump,"

stria, acne and hirsutism are

likely to occur if therapy is continued for more than a week or two.
However, these effects are dosage related and usually disappear within
several months after cessation of therapy.

The major concern is with

the "serious untoward reactions,,8 to steroid therapy.

These include

adrenal insufficiency, sodium and fluid retention, excess potassium
excretion, hyperglycemia and glycosuria, ttypertension, psychosis, convulsions, myopathy, osteoporosis with compression fractures of the
spine, peptic ulcers and the development and spread of bacterial and
viral infections.
untoward reactions.

A review of the controlled study reveals very few
Massell et al
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treated more than 200 rheumatic

patients for several weeks with significant doses of steroids and
reported that serious side effects were infrequent.

Furthermore, it

appears the risk is even further reduced if steroid therapy is shortterm and limited to a 7-10 day period.

3

Aspirin too, is not without

side effects such as hyperpnea, tinnitus and gastric irritation.
However, these effects are promptly controlled by dosage reduction,
and are of less serious nature than steroid reactions.

We must con-

clude then that the risk of steroid therapy is small but is a significant factor in the selection of a therapeutic regimen.
The U.K and U.S. Cooperative Study reported that the more prompt
control of acute manifestations by steroids was balanced by a greater

tendency for a reappearance of these manifestations following cessation of treatment.
phenomenon.

This reactivation has been termed the rebound

The severity of rheumatic fever during a rebound may be

as great or greater than at the start of treatment and residual heart
disease may result.

The mechanisms of the rebound phenomenon are

poorly understood, but it seems likely that an incomplete suppression
of the rheumatic process is a plausable explanation.

This would be

consistent with the higher incidence of this phenomenon in long-term
low dosage therapy such as employed in the U.

~

and U. S. study. Re-

bounds were non-existent with the short-term intensive therapy used in
the Combined Study (1965).

Salicylates should be used in the treat-

ment of rebounds as subsequent rebound is less likely after salicylates
than after steroids.
A third therapeutic disadvantage is the premature vigorous administration of suppressive agents before the signs and symptoms of rheumatic fever are unmistakable.

Both aspirin and steroids have been in-

dicted, but steroids appear to be the greater offender.

Stollerman
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points out that "after a well documented streptococcal infection the
conscientious physician may seek evidence suggestive of rheumatic fever,
such as persistence of an increased ESR, a prolonged PR interval in
the electrocardiogram, vague pains in the extremities, borderline temperature elevations, increased intensity of a functional murmur, and
tachycardia during the physical examination of an anxious or hyperactive
patient. II

The early use of steroids results in an ill defined syndrome,

only presumptively rheumatic fever, and the subsequent management of
the patient particularly the indications for long-term prophylaxis is
in doubt.

The emotional burdens that accompany the diagnosis and

management of rheumatic fever need not be enumerated.
co-workers
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Massell and

have pOinted out that patients with an acute onset of

rheumatic fever rarely show a long delay in the appearance of carditis
if this manifestation is going to occur.

In their large series of

patients, 76 per cent of the patients with evidence of heart damage
had cardiac involvement during the first week of illness.

The five

year U.K. and U.S, Cooperative Report confirmed Massell's findings and
added that prognosis is excellent in those patients with initial unequivocal evidence of carditis.

The diagnosis of acute rheumatic

fever should therefore be made conservatively and with insistence
upon clearly expressed major manifestations.
RECOMMENDATIONS
Having considered the various aspects of anti-rheumatic therapy
it now becomes possible to formulate a practical regimen.

Bed rest

and penicillin prophylaxis are very important elements in this regimen, but their discussion is beyond the scope of this paper.
Aspirin is the drug of choice for patients without rheumatic carditis.
Aspirin should also be the initial treatment for minimal carditis.
Markowitz and Kuttner
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define minimal carditis as questionable car-

diac enlargement, apical systolic murmurs of grade 1 or 2, AV dissociation of prolonged PR interval.

A dosage of 50 mg. of aspirin

per pound of body weight administered in six divided doses over 24
hours will usually result in an adequate blood level (25-35 mg%).
This dosage should be maintained until a satisfactory clinical response
is obtained, i.e. until the patient has complete relief of symptoms
a~d

signs of arthritis and the temperature has returned to normal

range,

Such response should occur within one to two weeks at which

time aspirin may be discontinued and the patient observed for about
ten days.
is needed.

If there is no recurrence of symptoms, no further therapy
In those patients in which fever or arthrit:gs persists or

recurs, aspirin is continued until all clinical symptoms have subsided.
However if aspirin does not appear to control the acute manifestations,
or if carditis becomes more definite, steroid therapy should be considered.

Children usually tolerate aspirin well and small amounts of

milk may be taken with each dose to reduce gastric irritation.

The

patient should be carefully watched for toxic manifestations such as
vomiting, tinnitus, and hyperpnea at which time the dosage should be
reduced appropriately.
Patients with moderate carditis should receive the benefits of
short-term steroid therapy.

Moderate carditis is arbitrarily defined

as the presence of grade 3 or louder apical systolic murmur, or an
aortic diastolic or mitral mid-diastolic murmur of any intensity.
dosage of steroid is debatable.

The

The Combined Study (1965) has recom-

mended 1 mg. of predisone per pound of body weight.

Rothman
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has more

recently pointed out that it is safer to err or the side of high dosage.
Perhaps then 2 mg/lb of body weight daily would also be acceptable.
is purely a matter of clinician preference.

It

The total dosage is divided

into four equal doses over a 24 hour period and continued until the acute
stage has subsided, the cardiac signs have stabilized, and the patient's
general condition has improved.

Such a response usually occurs within

7-10 days at which time the steroid can be discontinued abruptly and
salicylates begun.

Aspirin (50 mg/lb/day) is continued until all clini-

cal and laboratory signs of rheumatic activity have subsided.

Predni-

sone is preferred as it tends to cause fewer electrolyte disturbances

than other steroids.

Further minimization of electrolyte imbalance

is accomplished by using low salt diet.

In general. short-term

steroid therapy is well tolerated and Cushingoid side effects are
minimal.

Similarly, serious untoward effects and rebound phenomena

are rarely encountered when therapy is limited to a 7-10 day period.
Cardiac enlargement, pericarditis and congestive failure constitute severe carditis and a direct indication for steroid therapy.
However, no matter how promptly and completely the acute manifestations
are suppressed, residual rheumatic heart disease will not be prevented
in the majority of these patients.

Steroids are given primarily in

hope that they may be life saving.

Again this is a clinical impres-

sion and has not been scientifically documented.

Severe carditis

usually requires a somewhat longer course of therapy.
(1-2 mg/lb/day) should be continued for 2-4 weeks.

Prednisone

When steroids are

administered for more than ten days the dose must be tapered before
discontinuing therapy in order to prevent adrenal insufficiency due
to endogenous suppression.

In these patients, it is advisable to

overlap the steroid therapy with aspirin for one week before the steroid therapy is stopped so that rebound phenomena are minimized.

Aspi-

rin therapy should then be continued until all signs of rheumatic
activity have disappeared.
In view of the declining severity of rheumatic fever it is unlikely that a well controlled prospective study of the value of steroid therapy in critically ill patients with rheumatic carditis will
be possible in the near future.

Even at that, clinician bias is such

that the random selection of drugs in severely ill patients is generally thought to be contra-indicated.

Perhaps the following comments

by Nadas
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summarize the current trend of thought.

"While a1l this

(Cooperative Clinical Trial) was going on, members of the study group
made their own observations without the aid of IBM machines.

Other

investigators throughout the United States, Canada and England drew
their own conclusions without statisticians, as physicians have done
since time immemorial.

The almost unanimous conclusion was that from

the clinical view point the hormones were immensely useful indeed."
A review of the treatment of rheumatic carditis has been presented.

Controlled studies matching the effectiveness of salicylates

and steroids have been summarized and objectively criticized.

Ad-

vantages and limitations of both regimens have been discussed and
therapeutic recommendations proposed.
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